Bevacizumab in first-line treatment of metastatic breast cancer: A viewpoint by David Miles

Drugs

Volumn 67, Issue 12, 2007, Pages 1800-

  Miles, David ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; PACLITAXEL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PLACEBO; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; METASTASIS; NOTE; CANCER ADJUVANT THERAPY; DRUG CHOICE; DRUG INDICATION; ARTICLE; BREAST TUMOR; IMMUNOLOGY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547902073     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767120-00010     Document Type: Note

References (2)

1. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Sem Oncol 2003; 30 (5 Suppl. 16): 117-24
2. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23 (4): 792-9